Tobacco Addiction: Care and Services

Granda, José I. de; Carrión, F. Fernández; Alonso, Soledad; Marquez, Francisca; Riesco, Juan Antonio; Sampablo, Ítalo; Álvarez, Francisco Javier Quintana; Barrueco, M.; Carreras, José María Llamas; Jiménez, C.; Nerín, Isabel; Trullén, A. Pérez; Hermosa, Juan Luis Rodríguez; Romero, Pedro Juan Hernández; Agudo, L. Sánchez; Sánchez, Ignacio; Solano, S.; Álvarez-Sala, José Luis

doi:10.1016/s1579-2129(06)60594-6

Cited by 12 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The vast majority of scientific health care institutions recommend that public health services fund smoking-cessation treatments, 3 , 36 as they are considered to be one of the most effective health care interventions. 3 In addition, it must be noted that the only treatment that has proved to be effective in stopping COPD from progressing in patients who smoke is quitting smoking, and the COPD treatments currently available, apart from being expensive, are only symptomatic and are not able to stop the disease from progressing.…”

Section: Discussionmentioning

confidence: 99%

Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain

Jiménez-Ruíz¹,

Solano-Reina²,

Signes-Costa³

et al. 2015

COPD

View full text Add to dashboard Cite

The aim of the study was to assess the budgetary impact of funding smoking-cessation drugs in COPD patients in Spain. A hybrid model (cohort and Markov) was developed for a 5-year time horizon. Only approved cessation drugs (varenicline, bupropion, and nicotine replacement therapy) were considered. Irrespective of the drug, the model allowed for an initial cessation attempt, and up to three additional attempts in case of failure or smoking relapse during a 5-year period. Drug effectiveness was based on controlled clinical trials. National Health System perspective was applied; therefore, only medical resources were included. The pharmaceutical costs for smoking-cessation drugs, extra medical follow-up as a consequence of public reimbursement, and annual savings for health costs avoided due to stopping smoking were considered. The model estimated that 17,756 COPD patients would stop smoking if public funding was available, compared with 1,303 without reimbursement. In the reimbursement scenario, the savings accounted for a total of €48.0 million, compensating for expenditures on drugs and medical visits (€40.4 million). Accumulated total additional savings in 5 years (€4.3 million) compared with the scenario without reimbursement was shown. Sensitivity analyses supported the results robustness. Funding smoking-cessation drugs in COPD patients seems to be an efficient option and a National Health System drug reimbursement scheme would represent a cost-saving policy in Spain.

show abstract

Section: Discussionmentioning

confidence: 99%